What is the clinical significance
V2R is the unique validated therapeutic target for treating the autosomal dominant polycystic kidney disease, an unmet therapeutic need. MQ1 is a promising therapeutic agent against this disease. The MQ1/V2R interaction described here will help to improve MQ1 efficiency against this disease.